Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Trial Profile

Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs ARC 520 (Primary) ; Entecavir; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 13 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 01 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 15 Dec 2014 According to a media release, Arrowhead Research Corporation plans to submit additional clinical trial authorization applications with regulatory authorities in various jurisdictions in Europe and Asia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top